Literature DB >> 12649352

The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors.

Bo Rum Ryu1, Young Ae Lee, Seok Joon Won, Ji-Hyun Noh, Su-Youne Chang, Jun-Mo Chung, Jun Sub Choi, Choun Ki Joo, Sung Hwa Yoon, Byoung Joo Gwag.   

Abstract

Sulfasalazine is widely used to treat inflammatory diseases. Besides anti-inflammatory actions such as blockade of nuclear factor-kappaB and cyclooxygenases, we found that 30 to 1000 micro M sulfasalazine dose dependently blocked N-methyl-D-aspartate receptor-mediated excitotoxicity without intervening kainate or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid neurotoxicity. The neuroprotective effects of sulfasalazine were attributable to prevention of Ca(2+) influx and accumulation through N-methyl-D-aspartate receptors as a low-affinity antagonist. The systemic administration of sulfasalazine reduced neuronal death following transient cerebral and retinal ischemia in adult rat. The present findings suggest that the neuroprotective action of sulfasalazine can be therapeutically applied to halt devastating neuronal death following hypoxic ischemia, trauma, and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649352     DOI: 10.1124/jpet.102.042606

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

2.  Assessment at the single-cell level identifies neuronal glutathione depletion as both a cause and effect of ischemia-reperfusion oxidative stress.

Authors:  Seok Joon Won; Ji-Eun Kim; Giordano Fabricio Cittolin-Santos; Raymond A Swanson
Journal:  J Neurosci       Date:  2015-05-06       Impact factor: 6.167

3.  The functional and neuroprotective actions of Neu2000, a dual-acting pharmacological agent, in the treatment of acute spinal cord injury.

Authors:  Joe E Springer; Ravikumar Rangaswamy Rao; Hyang Ran Lim; Sung Ig Cho; Gyoeng Joon Moon; Hee Young Lee; Eui Jin Park; Jai Sung Noh; Byoung Joo Gwag
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

4.  Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.

Authors:  Carlos Gustavo Garcia; Suzana Assad Kahn; Luiz Henrique Medeiros Geraldo; Igor Romano; Ivan Domith; Deborah Christinne Lima E Silva; Fernando Dos Santos Assunção; Marcos José Ferreira; Camila Cabral Portugal; Jorge Marcondes de Souza; Luciana Ferreira Romão; Annibal Duarte Pereira Netto; Flávia Regina Souza Lima; Marcelo Cossenza
Journal:  Mol Neurobiol       Date:  2018-01-19       Impact factor: 5.590

5.  Chronic Sulfasalazine Treatment in Mice Induces System xc - - Independent Adverse Effects.

Authors:  Lise Verbruggen; Lindsay Sprimont; Eduard Bentea; Pauline Janssen; Azzedine Gharib; Lauren Deneyer; Laura De Pauw; Olaya Lara; Hideyo Sato; Charles Nicaise; Ann Massie
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

6.  Sulfasalazine decreases mouse cortical hyperexcitability.

Authors:  Oscar Alcoreza; Bhanu P Tewari; Allison Bouslog; Andrew Savoia; Harald Sontheimer; Susan L Campbell
Journal:  Epilepsia       Date:  2019-06-18       Impact factor: 5.864

7.  AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease.

Authors:  In-Sun Baek; Tae-Kyung Kim; Ji-Seon Seo; Kang-Woo Lee; Young Ae Lee; Jaeyoung Cho; Byoung Joo Gwag; Pyung-Lim Han
Journal:  Exp Neurobiol       Date:  2013-03-31       Impact factor: 3.261

8.  Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2.

Authors:  Teresa Kaserer; Veronika Temml; Zsofia Kutil; Tomas Vanek; Premysl Landa; Daniela Schuster
Journal:  Eur J Med Chem       Date:  2015-04-08       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.